<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristin M Leiferman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John J Zone, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 02, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H589229">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bullous pemphigoid and mucous membrane pemphigoid (MMP) are uncommon autoimmune subepithelial blistering diseases that most frequently arise in older adults and are characterized by the presence of cutaneous bullae and erosive mucosal lesions. Significant progress has been made in understanding the pathogenesis of these diseases. Multiple events, including the binding of immunoglobulins to basement membrane zone components, the subsequent activation of complement, and the migration of inflammatory cells into the subepithelial tissue, likely contribute to the clinical manifestations of bullous pemphigoid and MMP.
        </p>
        <p>
         The epidemiology and pathogenesis of bullous pemphigoid and MMP will be reviewed here. The clinical features, diagnosis, and treatment of these disorders and greater detail on the ocular form of MMP (ocular cicatricial pemphigoid) are available separately. (See
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15297.html" rel="external">
          "Management and prognosis of bullous pemphigoid"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83575.html" rel="external">
          "Management of mucous membrane pemphigoid"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">
          "Ocular cicatricial pemphigoid"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H589237">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pemphigoid disorders, which include bullous pemphigoid, MMP, anti-laminin 332 pemphigoid (also known as anti-epiligrin cicatricial pemphigoid), pemphigoid gestationis, Brunsting-Perry pemphigoid, and anti-laminin gamma-1 (anti-p200) pemphigoid, are characterized clinically by the presence of inflammatory, blistering, and/or erosive mucocutaneous lesions and immunohistopathologically by subepithelial cleavage and immunoglobulin G (IgG) and/or complement deposits in a linear pattern at the epidermal basement membrane zone (
         <a class="graphic graphic_picture graphicRef66267 graphicRef86373" href="/z/d/graphic/66267.html" rel="external">
          picture 1A-B
         </a>
         ). The location of blistering and immunoglobulin deposition distinguishes pemphigoid disorders from pemphigus. In pemphigus, blister formation and antibody deposition occur within the epidermis/epithelium (
         <a class="graphic graphic_picture graphicRef60749 graphicRef82837" href="/z/d/graphic/60749.html" rel="external">
          picture 2A-B
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of pemphigus"
         </a>
         .)
        </p>
        <p>
         MMP is not a single disease, rather it represents a group of heterogeneous, chronic subepithelial blistering diseases that primarily affect mucosal surfaces [
         <a href="#rid2">
          2
         </a>
         ]. Historically, because of the scarring sequelae that may develop clinically, the term
         <strong>
          cicatricial pemphigoid
         </strong>
         was ascribed to diseases now categorized as MMP.
        </p>
        <p>
         Some authors also consider mucosal-predominant forms of linear IgA bullous dermatosis and epidermolysis bullosa acquisita as forms of MMP [
         <a href="#rid2">
          2
         </a>
         ]. However, our preference is to consider these diagnoses as distinct disease entities. (See
         <a class="medical medical_review" href="/z/d/html/15301.html" rel="external">
          "Linear IgA bullous dermatosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15299.html" rel="external">
          "Epidermolysis bullosa acquisita"
         </a>
         .)
        </p>
        <p>
         A table summarizing the major forms of pemphigoid and non-pemphigoid autoimmune blistering disorders is provided (
         <a class="graphic graphic_table graphicRef76641" href="/z/d/graphic/76641.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H589244">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most of the data on the incidence of bullous pemphigoid are derived from European reports, in which studies documenting incidence rates of 4 to 22 cases per million individuals per year support the designation of bullous pemphigoid as an uncommon disorder [
         <a href="#rid3">
          3-5
         </a>
         ]. The results of retrospective studies suggest that the incidence of bullous pemphigoid may be increasing [
         <a href="#rid5">
          5-8
         </a>
         ]. One of the largest reported increases stems from a French, retrospective study that found that the annual incidence rate for bullous pemphigoid between 2000 and 2005 (22 cases per million inhabitants per year) was three times greater than the estimated incidence rate between 1986 and 1992 [
         <a href="#rid5">
          5
         </a>
         ]. Multiple factors may be contributing to the increased incidence of this disease, including the aging population and associated increase in neurologic conditions (which may be pathogenically linked), increased use of drugs implicated in drug-induced disease, and an increase in the diagnosis of variant pemphigoid forms including localized bullous pemphigoid [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
         Bullous pemphigoid is considered the most common autoimmune blistering disorder in Europe. However, in locations such as Thailand and Malaysia, pemphigus may be more common [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
         Bullous pemphigoid is primarily a disease of older adults; the vast majority of cases occur in individuals over the age of 60 years and occurrence in children is rare [
         <a href="#rid11">
          11-14
         </a>
         ]. In a retrospective study of 869 patients with bullous pemphigoid in the United Kingdom, the median patient age at the time of presentation was 80 years [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         The increased risk of bullous pemphigoid with advancing age was illustrated in two European prospective studies that were based upon data collected in 2001 and 2002 [
         <a href="#rid3">
          3,16
         </a>
         ]. In a German study, the estimated incidence rate in the general population was 13 cases per million individuals per year, but rose to 189 cases per million individuals per year among those over the age of 80 [
         <a href="#rid16">
          16
         </a>
         ]. Similarly, a sharp rise in incidence was evident in a Swiss study in which the incidence of bullous pemphigoid increased from 12 cases per million individuals per year in the general population to 163 cases per million individuals among those over the age of 90 [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         MMP is less common than bullous pemphigoid; in the German study cited above, the estimated incidence rate in the general population was two cases per million inhabitants per year [
         <a href="#rid16">
          16
         </a>
         ]. Like bullous pemphigoid, MMP is most likely to occur in older individuals and is rare in children [
         <a href="#rid11">
          11,17
         </a>
         ]. Patients with MMP most frequently are within the age range of 60 to 80 years [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Gender also may play a role in risk for bullous pemphigoid and MMP. Multiple studies have reported at least a slight female predominance in these disorders [
         <a href="#rid3">
          3,9,19
         </a>
         ]. The reasons for this observation are unknown.
        </p>
        <p class="headingAnchor" id="H589251">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanisms that lead to bullous pemphigoid and MMP are not fully understood, but most likely involve autoantibody-mediated damage to epithelial basement membrane zone, a complex structure that mediates adhesion, permeability, and cellular organization and differentiation (
         <a class="graphic graphic_figure graphicRef67891 graphicRef86896" href="/z/d/graphic/67891.html" rel="external">
          figure 1A-B
         </a>
         ) [
         <a href="#rid20">
          20-23
         </a>
         ]. The binding of antibodies to antigens within the epithelial basement membrane zone stimulates a destructive inflammatory cascade that results in separation of the epidermis from the dermis in skin and epithelium from subepithelial tissue in mucous membranes with the formation of characteristic cutaneous and mucosal lesions. Innate immune cells producing interleukin 17 (IL-17) may be important in the maintenance and extent of disease [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H783753">
         <span class="h2">
          Antigenic targets
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibodies to several antigens have been identified as potential contributors to bullous pemphigoid and MMP.
        </p>
        <p class="headingAnchor" id="H589258">
         <span class="h3">
          Bullous pemphigoid
         </span>
         <span class="headingEndMark">
          —
         </span>
         In bullous pemphigoid, autoantibodies against two principal hemidesmosomal proteins are strongly linked to clinical disease: bullous pemphigoid antigen 180 (BP180), a 180 kilodalton protein also known as bullous pemphigoid antigen 2 (BPAg2) and type XVII collagen, and bullous pemphigoid antigen 230 (BP230), a 230 kilodalton protein also referred to as bullous pemphigoid antigen 1 (BPAg1).
        </p>
        <p class="headingAnchor" id="H589265">
         <span class="h4">
          BP180
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibodies against BP180, a transmembrane protein that extends from the hemidesmosomal dense plaque in basal keratinocytes into the lamina densa of the basement membrane zone (
         <a class="graphic graphic_figure graphicRef67891" href="/z/d/graphic/67891.html" rel="external">
          figure 1A
         </a>
         ) [
         <a href="#rid25">
          25
         </a>
         ], are present in the majority of patients with bullous pemphigoid. Antibodies against the noncollagenous extracellular domain of BP180 known as NC16A (the primary site for antibody binding in bullous pemphigoid) are detected via enzyme-linked immunosorbent assay (ELISA) in 80 to 90 percent of affected patients [
         <a href="#rid21">
          21,26-31
         </a>
         ]. The production of antibodies to other epitopes of BP180 also occurs in bullous pemphigoid, and may have clinical significance. As an example, antibodies directed against epitopes in the C-terminal end of BP180 have been associated with the presence of mucosal disease [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
         An important role for antibodies against BP180 in bullous pemphigoid is supported by animal models in which the transfer of BP180 immunoglobulin (Ig)G antibodies resulted in the development of skin lesions that resemble bullous pemphigoid [
         <a href="#rid34">
          34-36
         </a>
         ] (see
         <a class="local">
          'Animal models'
         </a>
         below). Additional support is derived from the observation that serum levels of antibodies against the NC16A epitope correlate with disease activity [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
         The predominant subclass of antibodies that react with the basement membrane zone in bullous pemphigoid is immunoglobulin G4 (IgG4) [
         <a href="#rid39">
          39,40
         </a>
         ]. IgG4 antibodies also are present in the prodromal phase of bullous pemphigoid that often precedes cutaneous blistering [
         <a href="#rid40">
          40
         </a>
         ]. IgG1 and IgG2 antibodies may be present in bullous pemphigoid but are less frequently detected than IgG4 antibodies. IgG3 antibodies are usually absent [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Although BP180 antibodies of the IgG class are most frequently detected in bullous pemphigoid, IgA and IgE BP180 antibodies also may be present [
         <a href="#rid20">
          20,39-43
         </a>
         ]. The relevance of IgA antibodies in bullous pemphigoid remains uncertain. Cases in which a predominance of IgA basement membrane zone localization is detected actually may represent linear IgA bullous dermatosis (see
         <a class="medical medical_review" href="/z/d/html/15301.html" rel="external">
          "Linear IgA bullous dermatosis", section on 'Pathogenesis'
         </a>
         ). There is some evidence to support a pathogenic role for IgE basement membrane zone antibodies, including a small, retrospective study that identified an association with severe disease [
         <a href="#rid37">
          37,44-48
         </a>
         ]. In addition, a study in which anti-BP180 NC16A serum IgE was detected in 47 of 117 patients with BP (40 percent) found a correlation between serum levels of these autoantibodies and disease activity [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Of note, antibodies against BP180 also occur in other subepidermal autoimmune blistering diseases. IgG BP180 antibodies may be detected in patients with MMP and characteristically develop in pemphigoid gestationis. (See
         <a class="local">
          'Mucous membrane pemphigoid'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5564.html" rel="external">
          "Dermatoses of pregnancy", section on 'Pemphigoid gestationis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H589272">
         <span class="h4">
          BP230
         </span>
         <span class="headingEndMark">
          —
         </span>
         BP230 is an intracellular hemidesmosomal protein in the plakin family that is found in basal keratinocytes (
         <a class="graphic graphic_figure graphicRef67891" href="/z/d/graphic/67891.html" rel="external">
          figure 1A
         </a>
         ). In conjunction with plectin, another hemidesmosomal plakin, BP230 links keratin intermediate filaments to hemidesmosomes [
         <a href="#rid25">
          25
         </a>
         ]. Antibodies to BP230 are detected in approximately 60 to 70 percent of patients with bullous pemphigoid [
         <a href="#rid20">
          20,42
         </a>
         ]. The primary site of antibody binding on BP230 is the globular C-terminal domain [
         <a href="#rid20">
          20,42
         </a>
         ].
        </p>
        <p>
         It is unclear whether BP230 antibodies have a pathogenic role in bullous pemphigoid or whether they occur as a secondary event related to keratinocyte injury [
         <a href="#rid20">
          20,49
         </a>
         ]. Serum levels of antibodies against BP230 do not reveal consistent correlation with disease activity [
         <a href="#rid50">
          50-53
         </a>
         ]. In addition, the intracellular location of BP230 likely limits access of BP230 antibodies to the antigen.
        </p>
        <p>
         Nevertheless, there is a subset of pemphigoid patients with increased serum BP230 antibody levels and normal BP180 antibody levels [
         <a href="#rid53">
          53,54
         </a>
         ]. This finding may be more common in patients with nonbullous pemphigoid, a variant characterized by the absence of bullae, compared with patients with classic bullous pemphigoid [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H589279">
         <span class="h3">
          Mucous membrane pemphigoid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibodies against several basement membrane zone antigens have been detected in patients with MMP, some of which correlate with distinctive clinical features. The major basement membrane zone proteins targeted in MMP include (
         <a class="graphic graphic_figure graphicRef67891" href="/z/d/graphic/67891.html" rel="external">
          figure 1A
         </a>
         ) [
         <a href="#rid2">
          2,55-57
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         BP180 (C terminal domain)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         BP230
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laminin 332 (also known as laminin 5 or epiligrin)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alpha-6 beta-4 integrin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type VII collagen
        </p>
        <p>
        </p>
        <p>
         The precise location of antibody binding can have clinical relevance in MMP:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Scarring
         </strong>
         – The site of antibody binding may account for the frequent development of scarring in MMP lesions, a feature that typically is not observed in bullous pemphigoid. In contrast to bullous pemphigoid, in which antibody binding occurs to epitopes located in hemidesmosomes and the upper lamina lucida, antibody-binding in MMP is primarily located in the lower lamina lucida and lamina densa [
         <a href="#rid58">
          58
         </a>
         ]. This deeper location of antibody binding may increase the risk for scarring. (See
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Clinical features of mucous membrane pemphigoid'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sites of disease
         </strong>
         – Ocular involvement is associated with antibodies to the beta-4 integrin subunit of alpha-6 beta-4 integrin, whereas antibodies to the alpha-6 subunit have been linked to oral disease [
         <a href="#rid59">
          59,60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">
          "Ocular cicatricial pemphigoid", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A systematic review with pooled analysis found statistically significant associations between the detection of autoantibodies against laminin 332 with ELISA and both pharyngo-laryngeal and oro-pharyngo-laryngeal involvement in patients with MMP [
         <a href="#rid61">
          61
         </a>
         ]. However, publication bias may have contributed to this finding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk for associated malignancy
         </strong>
         – Antibodies to laminin 332, which are estimated to occur in approximately 25 percent of patients with MMP, are associated with an increased risk for internal malignancy [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Malignancy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In addition to the specific epitope or epitopes targeted, the number and type of autoantibodies that bind to the basement membrane zone may be clinically relevant in MMP. Autoantibodies to multiple basement membrane antigens or multiple epitopes on BP180, as well as the combined presence of IgG and IgA basement membrane zone antibodies have been associated with severe disease [
         <a href="#rid59">
          59,63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H783729">
         <span class="h3">
          Anti-p200 (laminin gamma-1) pemphigoid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laminins are heterotrimers composed of one of five alpha chains, one of four beta chains, and one of three gamma chains. The laminins are named based on their polypeptide chain assortment [
         <a href="#rid64">
          64
         </a>
         ]; for example, laminin 311 is composed of the laminin alpha-3, beta-1, and gamma-1 chains. At least 16 laminins are described of which at least three are important extracellular matrix glycoproteins in the basement membrane zone, laminin 311 (laminin 6), laminin 332 (laminin 5 or epiligrin), and laminin 551 (formerly known as laminin 10) [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         Anti-p200 (laminin gamma-1) pemphigoid is a type of pemphigoid that clinically resembles bullous pemphigoid [
         <a href="#rid66">
          66,67
         </a>
         ]. This type of pemphigoid is distinguished by the presence of antibodies to a 200 kilodalton protein that, in most patients, corresponds with the gamma-1 subunit of laminin 311 in the epithelial basement membrane zone (
         <a class="graphic graphic_figure graphicRef67891" href="/z/d/graphic/67891.html" rel="external">
          figure 1A
         </a>
         ) [
         <a href="#rid66">
          66,68-70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Anti-p200 (laminin gamma-1) pemphigoid'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H590340">
         <span class="h2">
          Role of pathogenic antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibody-mediated activation of the complement cascade by antibodies bound to specific antigens in the basement membrane zone has been proposed as a principal mechanism for lesion formation in bullous pemphigoid and MMP [
         <a href="#rid20">
          20,21,71,72
         </a>
         ]. The activation of complement may stimulate the local recruitment of inflammatory cells that release proinflammatory mediators as well as proteases that directly damage the basement membrane zone [
         <a href="#rid73">
          73,74
         </a>
         ]. In bullous pemphigoid, mast cells and eosinophils may contribute significantly to clinical disease [
         <a href="#rid75">
          75-80
         </a>
         ].
        </p>
        <p>
         Mechanisms other than complement-mediated pathways may also contribute to bullous pemphigoid and MMP. A case report describes a patient with nonbullous pemphigoid who was negative for BP180 antibodies but positive for BP230 and in whom direct and indirect immunofluorescence studies demonstrated deposition of only the IgG4 subclass of antibodies at the basement membrane zone [
         <a href="#rid53">
          53
         </a>
         ]. IgG4 antibodies are incapable of activating complement, supporting a complement-independent mechanism for the development of bullous pemphigoid.
        </p>
        <p>
         With respect to anti-p200 (laminin gamma-1) pemphigoid, an increasingly recognized form of pemphigoid [
         <a href="#rid81">
          81
         </a>
         ], ex vivo and in vivo studies were unable to show pathogenic activity of laminin gamma-1 antibodies [
         <a href="#rid82">
          82
         </a>
         ]. Such antibodies appear to be a useful biomarker for anti-p200 (laminin gamma-1) pemphigoid, but their pathogenic role is yet to be understood.
        </p>
        <p>
         The acceptance of basement membrane zone antibodies as the exclusive cause of bullous pemphigoid is complicated by the observation that some patients with positive circulating basement membrane zone antibodies lack clinical signs of disease [
         <a href="#rid83">
          83,84
         </a>
         ]. In one study, BP180, BP230, or both antibody levels determined by ELISA were increased in 5 out of 15 older adult patients with pruritus and no other clinical or laboratory evidence of bullous pemphigoid [
         <a href="#rid85">
          85
         </a>
         ]. It is unclear whether these results represented the identification of a prodromal phase of bullous pemphigoid or coincidental findings unrelated to the disease.
        </p>
        <p class="headingAnchor" id="H864458">
         <span class="h2">
          Animal models
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies utilizing animal models have contributed significantly to the understanding of the pathogenesis of bullous pemphigoid and MMP. The pathogenic role of BP180 antibodies is supported by animal models of bullous pemphigoid that indicate that IgG antibodies to a basement membrane zone antigen analogous to BP180 in the animal species are capable of activating complement and inducing features consistent with bullous pemphigoid, including blister development and mast cell degranulation [
         <a href="#rid34">
          34-36
         </a>
         ]. Moreover, passive transfer experiments in which human BP180 antibodies are delivered to mice humanized with BP180 antigen demonstrate basement membrane separation that is dependent upon complement, neutrophils, and mast cells [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
         However, the observations that animal models of bullous pemphigoid primarily demonstrate neutrophil infiltration (similar to that seen in linear IgA disease), rather than eosinophil infiltration and eosinophil degranulation, which are characteristic of human bullous pemphigoid, indicate that pathogenic mechanisms in bullous pemphigoid remain incompletely understood [
         <a href="#rid75">
          75,77,78
         </a>
         ]. It is likely that additional factors not present in the passive transfer models are responsible for eosinophil infiltration in humans. A murine model of bullous pemphigoid with IgE antibodies recapitulates the inflammatory infiltrate in pemphigoid more closely [
         <a href="#rid87">
          87
         </a>
         ]. Additional study is necessary to define the pathogenic role that IgE plays in bullous pemphigoid [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H589286">
         <span class="h2">
          Other factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although further study is necessary to elucidate the pathways that lead to bullous pemphigoid and MMP, genetic factors, environmental exposures, and the phenomenon of epitope spreading are considered potential contributory factors.
        </p>
        <p class="headingAnchor" id="H243306795">
         <span class="h3">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain human leukocyte antigen (HLA) alleles may play a role in bullous pemphigoid and MMP. In MMP, increased prevalence of the HLA-DQB1*0301 allele is reported in multiple studies [
         <a href="#rid89">
          89-92
         </a>
         ], and the same allele is associated with bullous pemphigoid in a small series of patients in the United States and Germany [
         <a href="#rid90">
          90,93
         </a>
         ]. However, these findings may not be applicable to all populations, as this allele was not associated with bullous pemphigoid in two studies performed in Japanese and Chinese patients [
         <a href="#rid94">
          94,95
         </a>
         ]. In the Japanese study, several other potential susceptibility alleles were identified [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         The proposed mechanism through which certain HLA alleles might contribute to risk for bullous pemphigoid or MMP involves the facilitation of antigen presentation of basement membrane zone antigens to T cells [
         <a href="#rid72">
          72
         </a>
         ]. Further studies are necessary to explore the role of genetic factors in the development of these diseases.
        </p>
        <p class="headingAnchor" id="H3835244742">
         <span class="h3">
          Infections and drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune reactions triggered by exposure to infections or drugs may play a role in bullous pemphigoid and MMP. In theory, these disorders could occur as a result of cross-reactivity of antibodies that target infectious agents or drugs with antigens in the basement membrane zone. Although no specific infectious disorder has been definitively associated with pemphigoid, in a small case-control study, antibodies against hepatitis B, hepatitis C,
         <em>
          Helicobacter pylori
         </em>
         ,
         <em>
          Toxoplasma gondii
         </em>
         , and cytomegalovirus were more prevalent among patients with bullous disease (pemphigus or bullous pemphigoid) [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         The possibility that pemphigoid is a rare side effect of vaccination against infectious agents is raised by reports of more than 25 patients with BP and at least 1 patient with MMP that describe the development of pemphigoid shortly after vaccination [
         <a href="#rid96">
          96,97
         </a>
         ]. However, a causal relationship between vaccination and pemphigoid is unconfirmed.
        </p>
        <p>
         A variety of drugs have been associated with the development of bullous pemphigoid [
         <a href="#rid98">
          98,99
         </a>
         ], although the strength of these associations is uncertain [
         <a href="#rid100">
          100
         </a>
         ]. A listing of many of the reported agents is provided (
         <a class="graphic graphic_table graphicRef130008" href="/z/d/graphic/130008.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         In particular, there is increasing support for an association between dipeptidyl peptidase-4 (DPP-4) inhibitors and the development of BP and MMP [
         <a href="#rid101">
          101-106
         </a>
         ]. A case-control study of 82 patients with BP and diabetes and 328 age- and sex-matched controls with diabetes but without BP found an association between DPP-4 inhibitor intake and the development of BP (adjusted odds ratio [OR] 3.2, 95% CI 1.9-5.4) [
         <a href="#rid107">
          107
         </a>
         ]. BP was associated with use of vildagliptin (adjusted OR 10.7, 95% CI 5.1-22.4) and
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         (adjusted OR 6.7, 95% CI 2.2-19.7), but not
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         . Patients younger than 70 years and males exhibited the strongest associations between DPP-4 inhibitor use and BP. Mucosal involvement in BP was more common in DPP-4 inhibitor-exposed patients. Patients who discontinued DPP-4 inhibitors appeared to have better outcomes from standard BP therapy than those who continued DPP-4 inhibitor use.
        </p>
        <p>
         Checkpoint inhibitors, including programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD-L1) blocking agents used for the treatment of cancer, constitute another class of drugs with pemphigoid as a dermatologic side effect [
         <a href="#rid99">
          99,108
         </a>
         ]. Various theories have been put forth to explain the pathophysiology underlying immune-related adverse events with this therapy. Generally, it is believed to be related to the role that checkpoints play in maintaining immunologic homeostasis.
        </p>
        <p class="headingAnchor" id="H4242727326">
         <span class="h3">
          Epitope spreading
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term epitope spreading has been used to describe the induction of an autoimmune response against normally tolerated host antigens and epitopes as a consequence of the exposure of these antigens and epitopes during immune-mediated tissue inflammation [
         <a href="#rid109">
          109
         </a>
         ]. Epitope spreading has been proposed as an explanation for cases in which pemphigoid occurred in the setting of other diseases. As examples, ocular cicatricial pemphigoid has developed following conjunctival inflammation due to Stevens-Johnson syndrome [
         <a href="#rid110">
          110
         </a>
         ] and, in lichen planus pemphigoides (a variant of bullous pemphigoid), the onset of bullous lesions occurs weeks to months after the development of lichen planus [
         <a href="#rid111">
          111
         </a>
         ]. Bullous pemphigoid also develops after radiation therapy possibly through exposure of basement membrane zone antigens in the course of the treatment [
         <a href="#rid112">
          112
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">
          "Ocular cicatricial pemphigoid", section on 'Pathogenesis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Clinical features of bullous pemphigoid'
         </a>
         .)
        </p>
        <p>
         Spreading of the immune response against epidermal basement membrane zone antigens to or from similarly structured proteins in other body sites also may occur. The development of bullous pemphigoid in several renal transplant patients has been attributed to the concept that autoantibody formation against the glomerular basement membrane zone may have contributed to the development of bullous disease [
         <a href="#rid113">
          113
         </a>
         ]. This phenomenon also has been proposed as a contributor to the observed link between bullous pemphigoid and certain neurologic disorders [
         <a href="#rid114">
          114-118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Neurologic disorders'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1525826217">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121560.html" rel="external">
          "Society guideline links: Bullous pemphigoid"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8432292">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/87300.html" rel="external">
          "Patient education: Bullous pemphigoid (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H783847">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bullous pemphigoid and mucous membrane pemphigoid (MMP) are uncommon autoimmune subepithelial bullous disorders that classically present with blistering and/or erosive cutaneous and mucosal lesions but also may present as urticaria, eczema, and/or pruritus (
         <a class="graphic graphic_table graphicRef76641" href="/z/d/graphic/76641.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Classification'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bullous pemphigoid and MMP primarily occur in the older population. Most patients affected by these disorders are over the age of 60 years. Bullous pemphigoid and MMP are rare in children. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical manifestations of bullous pemphigoid and MMP likely result from the destructive and inflammatory consequences related to antibody binding in the epithelial basement membrane zone in skin and mucous membranes. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bullous pemphigoid antigen 180 (BP180) and bullous pemphigoid antigen 230 (BP230) are two principal basement membrane zone antigens targeted by antibodies in patients with bullous pemphigoid (
         <a class="graphic graphic_figure graphicRef67891" href="/z/d/graphic/67891.html" rel="external">
          figure 1A
         </a>
         ). Although antibodies formed against BP180 are likely pathogenic, a pathogenic role for BP230 antibodies is uncertain. (See
         <a class="local">
          'Bullous pemphigoid'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple antigenic targets have been linked to MMP. Of note, antibodies against laminin 332 (also known as laminin 5 or epiligrin) are associated with an increased risk for malignancy, and antibodies against the beta-4 subunit of alpha-6 beta-4 integrin are linked to ocular disease (ocular cicatricial pemphigoid). (See
         <a class="local">
          'Mucous membrane pemphigoid'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Malignancy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">
          "Ocular cicatricial pemphigoid", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic factors, environmental exposures, and the phenomenon of epitope spreading may impact the development of bullous pemphigoid and MMP. Additional studies are necessary to explore the relationships of these factors to disease expression. (See
         <a class="local">
          'Other factors'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Baum S, Sakka N, Artsi O, et al. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev 2014; 13:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marazza G, Pham HC, Schärer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011; 29:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132:1998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Försti AK, Jokelainen J, Timonen M, Tasanen K. Increasing incidence of bullous pemphigoid in Northern Finland: a retrospective database study in Oulu University Hospital. Br J Dermatol 2014; 171:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brick KE, Weaver CH, Lohse CM, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol 2014; 71:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kridin K, Ludwig RJ. The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. Front Med (Lausanne) 2018; 5:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Prevalence and clinical features of Thai patients with bullous pemphigoid. Asian Pac J Allergy Immunol 2011; 29:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam BA. Bullous diseases in Malaysia: epidemiology and natural history. Int J Dermatol 1992; 31:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lara-Corrales I, Pope E. Autoimmune blistering diseases in children. Semin Cutan Med Surg 2010; 29:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011; 131:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisler RE, Saeb M, Liang MG, et al. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Am J Dermatopathol 2003; 25:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao CY, Chiang YZ, Murrell DF. Neonatal Autoimmune Blistering Disease: A Systematic Review. Pediatr Dermatol 2016; 33:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ 2008; 337:a180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertram F, Bröcker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009; 7:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kharfi M, Khaled A, Anane R, et al. Early onset childhood cicatricial pemphigoid: a case report and review of the literature. Pediatr Dermatol 2010; 27:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knudson RM, Kalaaji AN, Bruce AJ. The management of mucous membrane pemphigoid and pemphigus. Dermatol Ther 2010; 23:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity 2012; 45:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagi L, Baum S, Agmon-Levin N, et al. Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev 2011; 10:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishie W. Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII. J Dermatol Sci 2014; 73:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo Schiavo A, Ruocco E, Brancaccio G, et al. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol 2013; 31:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Jan S, Plée J, Vallerand D, et al. Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J Invest Dermatol 2014; 134:2908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs E, Raghavan S. Getting under the skin of epidermal morphogenesis. Nat Rev Genet 2002; 3:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mariotti F, Grosso F, Terracina M, et al. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol 2004; 151:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakuma-Oyama Y, Powell AM, Oyama N, et al. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J Dermatol 2004; 151:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnadas MA, Rubiales MV, González MJ, et al. Enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence testing in a bullous pemphigoid and pemphigoid gestationis. Int J Dermatol 2008; 47:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zillikens D, Mascaro JM, Rose PA, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997; 109:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002; 30:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishiura N, Fujimoto M, Watanabe R, et al. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 2008; 49:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofmann S, Thoma-Uszynski S, Hunziker T, et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 2002; 119:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Zenzo G, Grosso F, Terracina M, et al. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol 2004; 122:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Q, Ujiie H, Shibaki A, et al. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model. J Immunol 2010; 185:7746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ujiie H, Shibaki A, Nishie W, et al. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J Immunol 2010; 184:2166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heimbach L, Li N, Diaz A, Liu Z. Experimental animal models of bullous pemphigoid. G Ital Dermatol Venereol 2009; 144:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Döpp R, Schmidt E, Chimanovitch I, et al. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000; 42:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shirakata Y, Shiraishi S, Sayama K, Miki Y. Subclass characteristics of IgG autoantibodies in bullous pemphigoid and pemphigus. J Dermatol 1990; 17:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamb PM, Patton T, Deng JS. The predominance of IgG4 in prodromal bullous pemphigoid. Int J Dermatol 2008; 47:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kromminga A, Scheckenbach C, Georgi M, et al. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180. J Autoimmun 2000; 15:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010; 10:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Beek N, Lüttmann N, Huebner F, et al. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity. JAMA Dermatol 2017; 153:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodley DT. The role of IgE anti-basement membrane zone autoantibodies in bullous pemphigoid. Arch Dermatol 2007; 143:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairley JA, Burnett CT, Fu CL, et al. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007; 127:2605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwata Y, Komura K, Kodera M, et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008; 144:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arbesman CE, Wypych JI, Reisman RE, Beutner EH. IgE levels in sera of patients with pemphigus or bullous pemphigoid. Arch Dermatol 1974; 110:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saniklidou AH, Tighe PJ, Fairclough LC, Todd I. IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review. Arch Dermatol Res 2018; 310:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng M, Ujiie H, Iwata H, et al. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid. J Eur Acad Dermatol Venereol 2019; 33:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Zenzo G, Thoma-Uszynski S, Fontao L, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 2008; 128:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roussel A, Benichou J, Randriamanantany ZA, et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011; 147:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011; 147:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshimoto N, Takashima S, Kawamura T, et al. A case of non-bullous pemphigoid induced by IgG4 autoantibodies targeting BP230. J Eur Acad Dermatol Venereol 2021; 35:e282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meijer JM, Diercks GFH, de Lang EWG, et al. Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid. JAMA Dermatol 2019; 155:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rashid KA, Gürcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol 2006; 126:2631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan LS, Majmudar AA, Tran HH, et al. Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol 1997; 108:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarova Z, Yee C, Lazar J, Yancey KB. IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit. Clin Immunol 2001; 101:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bédane C, McMillan JR, Balding SD, et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 1997; 108:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oyama N, Setterfield JF, Powell AM, et al. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol 2006; 154:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zakka LR, Reche P, Ahmed AR. Role of MHC Class II genes in the pathogenesis of pemphigoid. Autoimmun Rev 2011; 11:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amber KT, Bloom R, Hertl M. A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti-laminin-332 IgG with oropharyngeal involvement and the usefulness of ELISA. J Eur Acad Dermatol Venereol 2016; 30:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt E, Skrobek C, Kromminga A, et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 2001; 145:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setterfield J, Shirlaw PJ, Bhogal BS, et al. Cicatricial pemphigoid: serial titres of circulating IgG and IgA antibasement membrane antibodies correlate with disease activity. Br J Dermatol 1999; 140:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aumailley M, Bruckner-Tuderman L, Carter WG, et al. A simplified laminin nomenclature. Matrix Biol 2005; 24:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domogatskaya A, Rodin S, Tryggvason K. Functional diversity of laminins. Annu Rev Cell Dev Biol 2012; 28:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meijer JM, Diercks GF, Schmidt E, et al. Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid. JAMA Dermatol 2016; 152:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kridin K, Ahmed AR. Anti-p200 Pemphigoid: A Systematic Review. Front Immunol 2019; 10:2466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dainichi T, Kurono S, Ohyama B, et al. Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci U S A 2009; 106:2800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groth S, Recke A, Vafia K, et al. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol 2011; 164:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dainichi T, Koga H, Tsuji T, et al. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid. J Dermatol 2010; 37:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu Z, Giudice GJ, Swartz SJ, et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995; 95:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA 2000; 284:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verraes S, Hornebeck W, Polette M, et al. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 2001; 117:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ståhle-Bäckdahl M, Inoue M, Guidice GJ, Parks WC. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest 1994; 93:2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dvorak AM, Mihm MC Jr, Osage JE, et al. Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J Invest Dermatol 1982; 78:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wintroub BU, Mihm MC Jr, Goetzl EJ, et al. Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N Engl J Med 1978; 298:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borrego L, Maynard B, Peterson EA, et al. Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am J Pathol 1996; 148:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein SM, Wasserman SI, Wintroub BU. Mast cell and eosinophil mediated damage in bullous pemphigoid. Immunol Ser 1989; 46:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amber KT, Valdebran M, Kridin K, Grando SA. The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease. Front Med (Lausanne) 2018; 5:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang H, Zhang Y, Li N, et al. The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury. Front Immunol 2018; 9:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau I, Goletz S, Holtsche MM, et al. Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin. J Am Acad Dermatol 2019; 81:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goletz S, Hashimoto T, Zillikens D, Schmidt E. Anti-p200 pemphigoid. J Am Acad Dermatol 2014; 71:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wieland CN, Comfere NI, Gibson LE, et al. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol 2010; 146:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang M, Lehman JS, Camilleri MJ, et al. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review. J Am Acad Dermatol 2019; 81:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feliciani C, Caldarola G, Kneisel A, et al. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses. Br J Dermatol 2009; 161:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu Z, Sui W, Zhao M, et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun 2008; 31:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zone JJ, Taylor T, Hull C, et al. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007; 127:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messingham KA, Holahan HM, Fairley JA. Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid. Immunol Res 2014; 59:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan LS, Hammerberg C, Cooper KD. Significantly increased occurrence of HLA-DQB1*0301 allele in patients with ocular cicatricial pemphigoid. J Invest Dermatol 1997; 108:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delgado JC, Turbay D, Yunis EJ, et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci U S A 1996; 93:8569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setterfield J, Theron J, Vaughan RW, et al. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol 2001; 145:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yunis JJ, Mobini N, Yunis EJ, et al. Common major histocompatibility complex class II markers in clinical variants of cicatricial pemphigoid. Proc Natl Acad Sci U S A 1994; 91:7747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büdinger L, Borradori L, Yee C, et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 1998; 102:2082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okazaki A, Miyagawa S, Yamashina Y, et al. Polymorphisms of HLA-DR and -DQ genes in Japanese patients with bullous pemphigoid. J Dermatol 2000; 27:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao XH, Winsey S, Li G, et al. HLA-DR and DQ polymorphisms in bullous pemphigoid from northern China. Clin Exp Dermatol 2002; 27:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sezin T, Egozi E, Hillou W, et al. Anti-laminin-332 mucous membrane pemphigoid developing after a diphtheria tetanus vaccination. JAMA Dermatol 2013; 149:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de la Fuente S, Hernández-Martín Á, de Lucas R, et al. Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review. Pediatr Dermatol 2013; 30:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 2014; 28:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 2018; 79:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan CW, Pang Y, Sim B, et al. The association between drugs and bullous pemphigoid. Br J Dermatol 2017; 176:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Díez I, Ivars-Lleó M, López-Aventín D, et al. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization. Int J Dermatol 2018; 57:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudin O, Seta V, Alexandre M, et al. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients. Front Immunol 2018; 9:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawaguchi Y, Shimauchi R, Nishibori N, et al. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. J Diabetes Investig 2019; 10:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arai M, Shirakawa J, Konishi H, et al. Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database. Diabetes Care 2018; 41:e130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SG, Lee HJ, Yoon MS, Kim DH. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes. JAMA Dermatol 2019; 155:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee H, Chung HJ, Pawar A, et al. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea. JAMA Dermatol 2020; 156:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kridin K, Bergman R. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. JAMA Dermatol 2018; 154:1152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apalla Z, Lallas A, Delli F, et al. Management of immune checkpoint inhibitor-induced bullous pemphigoid. J Am Acad Dermatol 2021; 84:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Zenzo G, Thoma-Uszynski S, Calabresi V, et al. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol 2011; 131:2271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan LS, Soong HK, Foster CS, et al. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA 1991; 266:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mignogna MD, Fortuna G, Leuci S, et al. Lichen planus pemphigoides, a possible example of epitope spreading. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen T, Kwan JM, Ahmed AR. Relationship between radiation therapy and bullous pemphigoid. Dermatology 2014; 229:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devaux S, Michot C, Mourad G, et al. Chronic renal graft rejection-associated bullous pemphigoid: A cross-reactive immune response? Acta Derm Venereol 2011; 91:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouras C, Riederer BM, Kövari E, et al. Humoral immunity in brain aging and Alzheimer's disease. Brain Res Brain Res Rev 2005; 48:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laffitte E, Burkhard PR, Fontao L, et al. Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis? Br J Dermatol 2005; 152:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen J, Li L, Chen J, et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology 2011; 57:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li L, Chen J, Wang B, et al. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald A, Schmidt E, Toberer F, et al. Overlap of Bullous, Anti-Laminin-332, and Anti-p200 Pemphigoid With Concomitant Anti-Contactin-1-Positive Inflammatory Polyneuropathy Treated With Intravenous Immunoglobulins as a Manifestation of Epitope Spreading. JAMA Dermatol 2019; 155:631.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16864 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24434358" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Diagnosis and classification of autoimmune blistering diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11902988" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19566661" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21605808" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical features and practical diagnosis of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22418872" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Incidence and mortality of bullous pemphigoid in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24934834" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Increasing incidence of bullous pemphigoid in Northern Finland: a retrospective database study in Oulu University Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24704091" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30177969" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21560490" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prevalence and clinical features of Thai patients with bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1737688" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Bullous diseases in Malaysia: epidemiology and natural history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20579597" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Autoimmune blistering diseases in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20944650" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Risk factors for bullous pemphigoid in the elderly: a prospective case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12775979" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Childhood bullous pemphigoid: a clinicopathologic study and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27086740" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Neonatal Autoimmune Blistering Disease: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18614511" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19170813" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20537062" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Early onset childhood cicatricial pemphigoid: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20597945" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The management of mucous membrane pemphigoid and pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3296406" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cicatricial pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21923615" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pemphigoid diseases: pathogenesis, diagnosis, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21527361" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24434029" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23806156" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24945093" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11972157" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Getting under the skin of epidermal morphogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15541078" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15270881" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19126009" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence testing in a bullous pemphigoid and pemphigoid gestationis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9347799" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12443845" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17920818" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12445194" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14962097" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21076071" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20089696" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19755945" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Experimental animal models of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10727301" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10677092" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2094743" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Subclass characteristics of IgG autoantibodies in bullous pemphigoid and pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18211485" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The predominance of IgG4 in prodromal bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11040070" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20713186" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Modern diagnosis of autoimmune blistering skin diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27829102" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17310005" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The role of IgE anti-basement membrane zone autoantibodies in bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17611576" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18209167" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4217592" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : IgE levels in sera of patients with pemphigus or bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29071428" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30394605" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18571472" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422336" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422334" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33219610" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A case of non-bullous pemphigoid induced by IgG4 autoantibodies targeting BP230.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30624575" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16810295" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Antigen specificity in subsets of mucous membrane pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9182809" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11580232" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9182819" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16403100" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21782980" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Role of MHC Class II genes in the pathogenesis of pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26446477" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti-laminin-332 IgG with oropharyngeal involvement and the usefulness of ELISA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11736901" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10233314" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cicatricial pemphigoid: serial titres of circulating IgG and IgA antibasement membrane antibodies correlate with disease activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15979864" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A simplified laminin nomenclature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23057746" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Functional diversity of laminins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27167149" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31695695" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Anti-p200 Pemphigoid: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19196964" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Anti-laminin gamma-1 pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20854435" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20507386" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7706459" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The role of complement in experimental bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10891967" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11710917" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8182134" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7035575" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/340950" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8774144" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2484955" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Mast cell and eosinophil mediated damage in bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30042946" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29545809" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30953703" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24767733" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Anti-p200 pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20083688" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30928465" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19485996" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18922680" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17235329" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24845463" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9008223" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Significantly increased occurrence of HLA-DQB1*0301 allele in patients with ocular cicatricial pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8710911" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11531829" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8052655" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Common major histocompatibility complex class II markers in clinical variants of cicatricial pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9854043" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10774139" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Polymorphisms of HLA-DR and -DQ genes in Japanese patients with bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12139680" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : HLA-DR and DQ polymorphisms in bullous pemphigoid from northern China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23700098" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Anti-laminin-332 mucous membrane pemphigoid developing after a diphtheria tetanus vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24125034" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24404939" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Drug-induced pemphigoid: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30025829" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27868192" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : The association between drugs and bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29682739" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29881377" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29920976" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30002201" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30624566" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32697283" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30090931" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32428613" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Management of immune checkpoint inhibitor-induced bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21697892" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1880886" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20382044" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Lichen planus pemphigoides, a possible example of epitope spreading.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24861031" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Relationship between radiation therapy and bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21088811" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Chronic renal graft rejection-associated bullous pemphigoid: A cross-reactive immune response?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15914253" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Humoral immunity in brain aging and Alzheimer's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15787824" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20664178" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19416254" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30892575" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Overlap of Bullous, Anti-Laminin-332, and Anti-p200 Pemphigoid With Concomitant Anti-Contactin-1-Positive Inflammatory Polyneuropathy Treated With Intravenous Immunoglobulins as a Manifestation of Epitope Spreading.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
